154 related articles for article (PubMed ID: 37694786)
1. Nanosuspension: A Formulation Technology for Tackling the Poor Aqueous Solubility and Bioavailability of Poorly Soluble Drugs.
Elsebay MT; Eissa NG; Balata GF; Kamal MA; Elnahas HM
Curr Pharm Des; 2023; 29(29):2297-2312. PubMed ID: 37694786
[TBL] [Abstract][Full Text] [Related]
2. Nanosuspension Technology: Recent Patents on Drug Delivery and their Characterizations.
Goel S; Sachdeva M; Agarwal V
Recent Pat Drug Deliv Formul; 2019; 13(2):91-104. PubMed ID: 31203813
[TBL] [Abstract][Full Text] [Related]
3. Nanosuspension-Based Drug Delivery Systems for Topical Applications.
Aldeeb MME; Wilar G; Suhandi C; Elamin KM; Wathoni N
Int J Nanomedicine; 2024; 19():825-844. PubMed ID: 38293608
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in Nanosuspension Technology for Drug Delivery.
Arora D; Khurana B; Rath G; Nanda S; Goyal AK
Curr Pharm Des; 2018; 24(21):2403-2415. PubMed ID: 29788880
[TBL] [Abstract][Full Text] [Related]
5. A formulation strategy for gamma secretase inhibitor ELND006, a BCS class II compound: development of a nanosuspension formulation with improved oral bioavailability and reduced food effects in dogs.
Quinn K; Gullapalli RP; Merisko-Liversidge E; Goldbach E; Wong A; Liversidge GG; Hoffman W; Sauer JM; Bullock J; Tonn G
J Pharm Sci; 2012 Apr; 101(4):1462-74. PubMed ID: 22213574
[TBL] [Abstract][Full Text] [Related]
6. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid-base neutralization approach.
Chougule M; Sirvi A; Saini V; Kashyap M; Sangamwar AT
Drug Deliv Transl Res; 2023 Oct; 13(10):2503-2519. PubMed ID: 37024611
[TBL] [Abstract][Full Text] [Related]
7. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
8. Fabrication of an aprepitant nanosuspension using hydroxypropyl chitosan to increase the bioavailability.
Liu J; Li S; Ao W; Li Y; Xiao Y; Bai M
Biochem Biophys Res Commun; 2022 Nov; 631():72-77. PubMed ID: 36179498
[TBL] [Abstract][Full Text] [Related]
9. BCS class IV drugs: Highly notorious candidates for formulation development.
Ghadi R; Dand N
J Control Release; 2017 Feb; 248():71-95. PubMed ID: 28088572
[TBL] [Abstract][Full Text] [Related]
10. Novel self-nanoemulsifying self-nanosuspension (SNESNS) for enhancing oral bioavailability of diacerein: Simultaneous portal blood absorption and lymphatic delivery.
El-Laithy HM; Basalious EB; El-Hoseiny BM; Adel MM
Int J Pharm; 2015 Jul; 490(1-2):146-54. PubMed ID: 26002566
[TBL] [Abstract][Full Text] [Related]
11. Solid Lipid Nanoparticles: A Potential Option for Enhancing Oral Bioavailability of Highly Soluble and Poorly Permeable (BCS Class III) Drugs.
Sri Rekha M ; Sangeetha S ; Seetha Devi A
Curr Drug Deliv; 2023; 20(3):223-236. PubMed ID: 35443896
[TBL] [Abstract][Full Text] [Related]
12. Fabrication of surfactant-stabilized nanosuspension of naringenin to surpass its poor physiochemical properties and low oral bioavailability.
Singh MK; Pooja D; Ravuri HG; Gunukula A; Kulhari H; Sistla R
Phytomedicine; 2018 Feb; 40():48-54. PubMed ID: 29496174
[TBL] [Abstract][Full Text] [Related]
13. Amorphous nano morin outperforms native molecule in anticancer activity and oral bioavailability.
Jangid AK; Agraval H; Gupta N; Jain P; Yadav UCS; Pooja D; Kulhari H
Drug Dev Ind Pharm; 2020 Jul; 46(7):1123-1132. PubMed ID: 32469607
[TBL] [Abstract][Full Text] [Related]
14. [Research progress on
Shen BD; Shen CY; Xu LX; Zhu WF; Yuan HL
Zhongguo Zhong Yao Za Zhi; 2018 Oct; 43(19):3828-3833. PubMed ID: 30453705
[TBL] [Abstract][Full Text] [Related]
15. Preparation, characterization and pharmacokinetics of cyadox nanosuspension.
Sattar A; Chen D; Jiang L; Pan Y; Tao Y; Huang L; Liu Z; Xie S; Yuan Z
Sci Rep; 2017 May; 7(1):2289. PubMed ID: 28536446
[TBL] [Abstract][Full Text] [Related]
16. Nanosuspension: An approach to enhance solubility of drugs.
Patel VR; Agrawal YK
J Adv Pharm Technol Res; 2011 Apr; 2(2):81-7. PubMed ID: 22171298
[TBL] [Abstract][Full Text] [Related]
17. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
[TBL] [Abstract][Full Text] [Related]
18. Nanosuspension Technology For Poorly Soluble Drugs: Recent Researches, Advances and Patents.
Agarwal V; Bajpai M
Recent Pat Nanotechnol; 2015; 9(3):178-94. PubMed ID: 27009133
[TBL] [Abstract][Full Text] [Related]
19. Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation.
Alshweiat A; Csóka I; Tömösi F; Janáky T; Kovács A; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Szabó-Révész P; Ambrus R
Int J Pharm; 2020 Apr; 579():119166. PubMed ID: 32084574
[TBL] [Abstract][Full Text] [Related]
20. Design of dry nanosuspension with highly spontaneous dispersible characteristics to develop solubilized formulation for poorly water-soluble drugs.
Niwa T; Miura S; Danjo K
Pharm Res; 2011 Sep; 28(9):2339-49. PubMed ID: 21626059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
